

CURRICULUM VITAE

David Weill, M.D.



Current Position Title: Principal, Weill Consulting Group

Work Address: Weill Consulting Group
5935 Magazine Street, New Orleans, LA 70115
Telephone (office): (504) 558-4942
E-Mail: david@weillconsulting.com

License No: C52127 (CA); ME 130463 (FL); 304283 (LA)
Place of Birth: New Orleans, LA
Citizenship: U.S.
Marital Status: Married

Undergraduate Education: **1985** Bachelor of Arts, Political Science, Tulane University, New Orleans, LA
Cum Laude

Graduate Education: **1990** M.D., Tulane University Medical School

Postdoctoral Training: **06/90-06/93** Internship and Residency in Internal Medicine, Parkland Hospital, University of Texas - Southwestern
07/93-06/96 Fellowship in Pulmonary and Critical Care Medicine and Lung Transplantation, University of Colorado at Denver and Health Sciences Center (UCDHSC)

Honors and Awards: **2010** Cystic Fibrosis Research Institute, Professional of the Year

Licensure and Certification: **1993 - 2003** American Board of Internal Medicine, Internal Medicine
1996 Diplomate in Pulmonary Disease (recertified until 2026)
2006 Diplomate in Critical Care Medicine

GRANTS:

Present/Pending: **2011-2014** National Institutes of Health, RC4, RFA-OD-10-005
Genome Transplant: A non-invasive sequencing-based method for detecting acute and chronic rejection of solid organ transplants
Co-investigator, 5% effort (Principal Investigators: Hannah Valentine/Steve Quake)

2011-2013 National Institutes of Health, Program Project Grant
Elafin Therapy of Lung Disease
Co-investigator (Principal Investigator: Marlene Rabinovitch)

2010-2012 National Institutes of Health, NHLBI, R34RFA-HL-10-016
Antibody-mediated rejection in lung transplantation
Principal investigator, 2.5% effort

Present/Pending:

2008-2012 APT Pharmaceuticals, Inc., CIS001

The goal of this study is to assess the effectiveness of inhaled cyclosporine in preventing chronic rejection following lung transplantation.

Dr. Weill is the site Principal Investigator

5% effort, \$ 275,351 direct costs/yr

A multi-center, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of cyclosporine inhalation solution (CIS) in improving bronchiolitis obliterans syndrome-free survival following lung transplantation

2009-2011 Translational Therapeutics Development Center

Cystic Fibrosis Foundation Therapeutics, Inc MILLA09Y0

Dr. Weill is the Co-Principal Investigator

(Principal Investigator: Carlos Milla)

The major goal of this project is to establish infrastructure support for a clinical trials network related to cystic fibrosis.

2008-2011 Program for Adult Care Excellence

Cystic Fibrosis Foundation, WEILL08ACO

Dr. Weill is the Principal Investigator

The major goal of this project is to enhance the training of adult physicians in the care of adult patients with cystic fibrosis.

2007-2011 National Institutes of Health

A Multi-center Prospective Cohort Study Examining the Role of Protein

C in Early ARDS

Co-investigator (Principal Investigator: Ann Weinacker)

Goal: Participate in a multicenter trial examining primary graft injury after lung transplantation

Responsibilities: Coordinate patient selection and monitoring with the PI

2001-2011 Cystic Fibrosis Center Grant

Cystic Fibrosis Foundation C011-09

Dr. Weill is the Co-Principal Investigator (Principal Investigator: Carlos Milla)

The major goal of this project is to provide infrastructure support to the Stanford Cystic Fibrosis Center.

APPOINTMENTS:

Professional:

07/96-11/99 Medical Director, Lung and Heart – Lung Transplant Program

Medical City Hospital

Dallas, TX

Academic:

04/2017 – present Professor of Medicine and Surgery

Morsani College of Medicine

University of South Florida Health

08/01/11 – 07/01/16 Professor of Medicine

Stanford University School of Medicine

05/01/06- 07/31/11 Associate Professor of Medicine

Medical Director, Lung and Heart – Lung Transplant Program

Stanford University School of Medicine

12/31/05-04/30/06 Acting Associate Professor

Stanford University School of Medicine

06/02-11/05 Associate Professor of Medicine
Associate Director, Lung and Heart – Lung Transplant Program
University of Colorado Health Sciences Center

12/99-05/02 Associate Professor of Medicine
Medical Director, Lung and Heart – Lung Transplant Program
University of Alabama – Birmingham

Other Appointments:

06/01/17-present Director, Institute for Advanced Organ Failure and Transplantation
Tampa General Hospital/University of South Florida Health

12/05 – 10/15 Director, Center for Advanced Lung Diseases
Medical Director, Lung and Heart – Lung Transplant Program, Stanford University Medical Center

09/08-07/13 Director, Adult Cystic Fibrosis Program, Stanford University School of Medicine

EDITORIAL BOARD MEMBERSHIPS:

1999-2009 Associate Editor, The Journal of Heart and Lung Transplantation

Peer Review Activities:

2014- Present American Journal of Respiratory and Critical Care Medicine

2014- Present Journal of Toxicology and Environmental Health

2014- Present Thorax

2014- Present Critical Reviews in Toxicology

2013- Present The New England Journal of Medicine

1996- Present The Journal of Heart and Lung Transplantation

1996- Present American Journal of Transplantation

1996- Present The Journal of Chronic Obstructive Pulmonary Disease

1996- Present Chest

1996- Present Clinical Transplantation

MAJOR COMMITTEE AND SERVICE RESPONSIBILITIES (ADMINISTRATION)

Divisional:

2007- 2008 Search Committee, Director, Adult Cystic Fibrosis Program, Stanford
2004- 2005 Finance Committee, Division of Pulmonary and Critical Care, University of Colorado Health Sciences Center

Departmental:

2010- 2012 Strategic Planning Committee, Department of Medicine, Stanford

SOM:

2008-Present Quality Council (Co-Chair), Transplantation PPEC, Stanford

2013-2015 Search Committee Chair, Surgical Director, Lung Transplantation, Cardiothoracic Surgery, Stanford

2010-2012 Faculty Fellow, Stanford

2008-2011 Quality Council, Cardiothoracic Surgery, Stanford

2006-2007 Search Committee, Head, Thoracic Surgery, Cardiothoracic Surgery, Stanford

2007 Hand Hygiene Physician Task Force, Stanford

2006 Search Committee, Pediatric Pulmonary Biology Center Faculty Member, Stanford

2002- 2005 Antimicrobial Subcommittee, Pharmacy and Therapeutics Committee, University of Colorado Health Sciences Center

Leadership Roles:

2009-2015 Director, Center for Advanced Lung Disease, Stanford University Medical Center

2005-2015 Medical Director, Lung and Heart – Lung Transplant Program, Stanford University Medical Center

2008-2013 Director, Adult Cystic Fibrosis Center, Stanford University Medical Center

Professional Society
Leadership Roles:

2008-present Member, Medical Advisory Board, California Transplant Donor Network
2014-2016 Past Chair, Pulmonary Transplantation Council, International Society of Heart and Lung Transplantation
2012-2014 Chair, Pulmonary Transplantation Council, International Society of Heart and Lung Transplantation
2014-2015 Section Editor, ISHLT's reference guide for the work-up and diagnosis of common syndromes in thoracic organ transplant recipients
2009-2011 Vice-Chair, Pulmonary Transplantation Council, International Society of Heart and Lung Transplantation
2008-2011 Pulmonary Council Leader, Standard and Guidelines Committee, International Society of Heart and Lung Transplantation

Meeting Session
Chairman

Novel Mechanisms in Chronic Lung Allograft Dysfunction, International Society of Heart and Lung Transplantation, April 7, 2017
Advances in Immunosuppression, International Society of Heart and Lung Transplantation, San Diego, April 14, 2014
ISHLT Academy: Core Competencies in Lung Transplantation, International Society of Heart and Lung Transplantation, San Diego, April 13, 2011
The Lung Allocation System, International Society of Heart and Lung Transplantation, Paris, April 23, 2009
Advances in Immunosuppression, International Society of Heart and Lung Transplantation, San Francisco, April 27, 2009
Controversies in Cardiothoracic Transplantation, Cardiothoracic Transplantation: An International Update, Vail, CO, February 22, 2003
Clinical Lung Transplantation, International Society for Heart and Lung Transplantation, Osaka, Japan, April 6, 2000

Committee:

2017 Committee Member, Identifying Collaborative Clinical Research Priorities in Lung Transplantation, National Heart, Lung, and Blood Institute/AATS
2007- Present Abstract Reviewer, International Meeting, International Society of Heart and Lung Transplantation
2014-2016 Member, Thoracic Committee, United Network for Organ Sharing
2008- 2010 Member, Communications Committee, International Society of Heart and Lung Transplantation
2006-2008 Member, Membership and Professional Standards Committee, United Network for Organ Sharing
2005-2006 Member, National Lung Review Board, United Network for Organ Sharing
2003 Member, Working Group on Primary Lung Graft Failure, International Society of Heart and Lung Transplantation
2001 Member, Maximizing Cadaveric Organ Utilization, American Society of Transplantation

TEACHING RECORD:

Curriculum Development:

Lung Transplant Fellowship
Stanford University Medical Center
2005-2015

Lung Transplant Fellowship
University of Colorado Health Sciences Center
2002-2005

Lung Transplant Fellowship
University of Alabama – Birmingham
1999-2002

Governmental Consulting: United States Senate
Environment and Public Works
The Health Effects of Asbestos
June 2007

United States Senate
Judiciary Committee Testimony
Asbestos and Mixed Dust Disease
February 2005

Texas State Legislature Testimony
House Bill 8 Regarding Asbestos and Silica
March 2005

Scientific Consulting: Chair, Scientific Advisory Board
National Sand, Stone, and Gravel Association
2012 - present

PUBLICATIONS:

Peer-Reviewed Articles

1. Snell GI, Snell GI, Yusen RD, **Weill D**, Strueber M, Garrity E, Reed A, Pelaez A, Whelan TP, Perch M, Bag R, Budev M, Corris PA, Crespo MM, Witt C, Cantu E, Christie JD. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and Grading – A 2016 Consensus group statement of the International Society for the Heart and Lung Transplantation J Heart Lung Transplant. 2017 Oct;36(10):1097-1103
2. Cantu E, Diamond JM, Suzuki Y, Lasky J, Schaufler C, Lim B, Shah R, Porteous M, Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Borhade S, Bermudez C, Crespo M, McDyer J, Wille K, Orens J, Shah PD, Weinacker A, **Weill D**, Wilkes D, Roe D, Hage C, Ware LB, Bellamy SL, Christie JD; Lung Transplant Outcomes Group. Am J Respir Crit Care Med. 2017 Sep 5
3. Pasupneti S, Patel K, Mooney JJ, Chhatwani L, Dhillon G, **Weill D**. Lung transplantation following death by drowning: a review of the current literature. Clin Transplant. 2016 Oct.
4. Mooney JJ, **Weill D**, Boyd JH, Nicolls MR, Bhattacharya J, Dhillon GS. Effect of Transplant Center Volume on Cost and Readmissions in Medicare Lung Transplant Recipients. Ann Am Thorac Soc. 2016 Apr 11.
5. Yang RL, Kurian AW, Winton LM, **Weill D**, Patel K, Kingham K, Wapnir IL. Addressing inherited predisposition for breast cancer in transplant recipients. J Surg Oncol. 2016 Feb.
6. Yang RL, Kurian AW, Winton LM, **Weill D**, Patel K, Kingham K, Wapnir IL. Addressing inherited predisposition for breast cancer in transplant recipients. J Surg Oncol. 2016 Feb.
7. Cantu E, Suzuki Y, Diamond JM, Ellis J, Tiwari J, Beduhn B, Nellen JR, Shah R, Meyer NJ, Lederer DJ, Kawut SM, Palmer SM, Snyder LD, Hartwig MG, Lama VN, Borhade S, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, **Weill D**, Wilkes D, Roe D, Ware LB, Wang F, Feng R, Christie JD. Lung Transplant Outcomes Group. Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk. Am J Transplant. 2015 Dec.
8. Hill C, Maxwell B, Boulate D, Haddad F, Ha R, Afshar K, **Weill D**, Dhillon GS. Heart-lung vs. double-lung transplantation for idiopathic pulmonary arterial hypertension. Clin Transplant. 2015 Dec;29(12):1067-75.
9. Iwijn De Vlamincq, Lance Martina, Michael Kertesza, Kapil Patel, Mark Kowarskya, Calvin Strehle, Garrett Cohene, Helen Luikart, Norma F. Neff, Jennifer Okamoto, Mark R. Nicolls, David Cornfield, **Weill D**, Hannah Valantine, Kiran K. Khush, and Stephen R. Quake. Noninvasive monitoring of infection and rejection after lung transplantation. PNAS. 2015 Oct;112(43):13336-41.
10. **Weill D**, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A consensus document for the selection of lung transplant candidates: 2014 – an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015 Jan;34(1):1-15.

11. Maxwell BG, Mooney JJ, Lee PH, Levitt JE, Chhatwani L, Nicolls MR, Zamora MR, Valentine V, **Weill D**, Dhillon GS. Increased resource utilization in lung transplant admissions in the Lung Allocation Score era. *Am J Respir Crit Care Med*. 2014 Dec 17.
12. Maxwell BG, Levitt JE, Goldstein BA, Mooney JJ, Nicolls MR, Zamora M, Valentine V, **Weill D**, Dhillon GS. Impact of the lung allocation score on survival beyond 1 year. *Am J Transplant*. 2014 Oct;14(10):2288-94.
13. De Vlaminck I, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, Okamoto J, Snyder TM, Cornfield DN, Nicolls MR, **Weill D**, Bernstein D, Valentine HA, Quake SR. Temporal response of the human virome to immunosuppression and antiviral therapy. *Cell* 2013 Nov 21;155(5):1178-87.
14. Diamond JM, Porteous MK, Cantu E, Meyer NJ, Shah RJ, Lederer DJ, Kawut SM, Lee J, Bellamy SL, Palmer SM, Lama VN, Borhade SM, Crespo M, Demissie E, Wille K, Orens J, Shah PD, Weinacker A, **Weill D**, Arcasoy S, Wilkes DS, Ware LB, Christie JD; Lung Transplant Outcomes Group. Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. *PLoS One* 2012;7(12):e51932.
15. Diamond JM, Meyer NJ, Feng R, Rushefski M, Lederer DJ, Kawut SM, Lee JC, Cantu E, Shah RJ, Lama VN, Borhade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, **Weill D**, Arcasoy S, Shah PD, Belperio JA, Wilkes D, Ware LB, Palmer SM, Christie JD. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. *Am J Respir Crit Care Med* 2012 Sep 15;186(6):546-52.
16. Dhillon G, Valentine V, Levitt J, Gupta M, Duncan S, Seoane L, and **Weill D**. Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. *Clinical Transplantation*. 2012 Jan-Feb;26(1):105-10.
17. Diamond JM, Lederer DJ, Kawut SM, Lee J, Ahya VN, Bellamy S, Palmer SM, Lama VN, Borhade S, Crespo M, Demissie E, Sonnett J, Wille K, Orens J, Sha PD, Weinacker A, **Weill D**, Kohl BA, Deutschman CC, Arcasoy S, Shah AS, Belperio JA, Wilkes D, Reynolds JM, Ware LB, Christie JD. Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis. *Am J Transplant* 2011 Nov;11(11):2517-22.
18. Liu V, **Weill D**, Bhattacharya J. Racial Disparities in Survival After Lung Transplantation. *Arch Surg* 2011 Mar;146(3):286-93.
19. Liu V, Bhattacharya J, **Weill D**, Hunt S, and Hlatky MA. Persistent racial disparities in survival following heart transplantation. *Circulation* 2011 Apr 19;123(15):1642-9. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.
20. **Weill D**, Dhillon G, Freyder L, Lefante J, and Glindmeyer H. Lung function, radiologic changes, and exposure: analysis of ATSDR data from Libby, Montana. *European Respiratory Journal* 2011 Aug;38(2):376-83.
21. Dhillon GS, Zamora MR, Roos JE, Sheahan D, Sista RR, van der Starre P, **Weill D**, Nicolls MR. Lung transplant airway hypoxia: a diathesis to fibrosis. *Am J Respir Crit Care Med*. 2010 Jul 15;182(2):230-6. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.
22. Deuse T, Sista R, **Weill D**, Haddad F, Dhillon G, Robbins RC, and Reitz BA. Review of heart-lung transplantation at Stanford. *Ann Thorac Surg* 2010 Jul; 90(1):329-37. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.
23. Chang W, Wei K, Jacobs SS, Upadhyay D, **Weill D**, and Rosen GD. SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. *J Biol Chem*. 2010 Mar 12;285(11):8196-206. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.
24. Liu V, Zamora MR, Dhillon GS, and **Weill D**. Increasing Lung Allocation Scores Predict Worsened Survival among Lung Transplant Recipients. *American Journal of Transplantation* 2010 Apr;10(4):915-20.
25. Liu V, Dhillon GS, and **Weill D**. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. *Transpl Infect Dis* 2010 Feb;12(1):38-44.
26. Choi JY, Khansaheb M, Joo NS, Krouse ME, Robbins RC, **Weill D**, and Wine JJ. Substance P stimulates airway submucosal gland secretion mainly via a CFTR – dependent

process. *Journal of Clinical Investigation* 2009 May;119(5):1189-200. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.

27. Valentine VG, **Weill D**, Lombard GA, LaPlace SG, Seoane L, Taylor DE, Dhillon GS. A Single Institution Study Evaluating the Utility of Surveillance Bronchoscopy Following Lung Transplantation. *Journal of Heart and Lung Transplantation* 2009 Jan;28(1):14-20. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.

28. Dhillon GS, Levitt J, Mallidi H, Valentine VG, Gupta MR, Sista R, and **Weill D**. Impact of Hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the United Network for Organ Sharing database. *Transplantation* 2009; 88:842-846.

29. Valentine VG, **Weill D**, Raper B, Lombard GA, LaPlace SG, Bonvillain RW, Seoane L, Taylor DE, Dhillon GS. Ganciclovir for Cytomegalovirus: A Call for Indefinite Prophylaxis in Lung Transplantation. *Journal of Heart and Lung Transplantation* 2008 Aug;27(8):875-81. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.

30. Leung M, Rachakonda L, **Weill D**, and Hwang P. Outcomes of Sinus Surgery before Lung Transplantation for Cystic Fibrosis. *American Journal of Rhinology* 2008 Mar –Apr; 22(2): 192 – 6. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.

31. Mulligan MS, Shearon TH, **Weill D**, Pagani FD, Moore J, and Murray S. Heart and Lung Transplantation in the United States, 1997-2006. *American Journal of Transplantation* 2008 Apr; 8(4 Pt 2):977-87. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.

32. Astor TL, **Weill D**, Cool C, Teitlebaum I, Schwarz MI and Zamora MR. Pulmonary capillaritis in lung transplant recipients: treatment and effect on allograft function. *Journal of Heart and Lung Transplantation* 2005; 24:2091-7. My primary role in this study was to provide significant editing to the manuscript. I also took the primary responsibility for answering the reviewers' questions.

33. Christie JD, Carby M, Bag R, Corris P, Hertz M, and **Weill D**. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A Consensus Statement of the International Society for Heart and Lung Transplantation. *Journal of Heart and Lung Transplantation* 2005 Oct; 24(10):1454-9.

34. Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor TL, Grazia T, and **Weill D**. Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung Transplantation. *American Journal of Transplantation* 2004 Oct; 4(10):1635-42.

35. Dransfield MT, Garver RI, and **Weill D**. Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients. *Journal of Heart and Lung Transplantation* 2004; 23(1):110-4.

36. Zorn GL, McGiffin DC, Young KR, Alexander CB, **Weill D**, and Kirklin JK. Pulmonary transplantation for advanced bronchioloalveolar carcinoma. *Journal of Thoracic and Cardiovascular Surgery* 2003; 125(1):45-8. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.

37. **Weill D**, Lock BJ, Wewers DL, Young KR, Zorn GL, Early L, Kirklin JK, and McGiffin DC. Combination prophylaxis with ganciclovir and cytomegalovirus immune globulin after lung transplantation: Effective CMV prevention following daclizumab induction. *American Journal of Transplantation* 2003; 3(4):492-496.

38. **Weill D**, Dey GC, Hicks RA, Young KR, Zorn GL, Kirklin JK, Early L, and McGiffin DC. A positive donor gram stain does not predict outcome following lung transplantation. *Journal of Heart and Lung Transplantation* 2002; 21(5):555-8.

39. Schmidt F, McGiffin DC, Zorn G, Young KY, **Weill D**, and Kirklin JK. Management of congenital abnormalities of the donor lung. *Annals of Thoracic Surgery* 2001; 72(3):935-7. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.

- 40.** Nemunaitis J, Swisher SG, Mack M, **Weill D**, Merritt J, and Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small cell lung cancer. *Journal of Clinical Oncology* 2000; 18(3):609-622. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.
- 41.** **Weill D**, Mack MJ, Roth J, Swisher S, Proksch, Merritt J, and Nemunaitis J. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. *Chest* 2000; 118:966-70.
- 42.** **Weill D**, McGiffin DC, Zorn GL, Alexander CB, Early LJ, Kirklin JK, and Young KR. The utility of open lung biopsy following lung transplantation. *Journal of Heart and Lung Transplantation* 2000; 19(9):852-857.
- 43.** Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Savin M, Schump DS, Shin DM, Shulkin A, Walsh GL, Wait J, **Weill D**, and Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. *J Natl Cancer Inst.* 1999 May 5; 91(9):763-71. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.
- 44.** **Weill D**, Hodges TN, Torres F, and Zamora MR. Acute native lung hyperinflation is not associated with a poor outcome following single lung transplantation for emphysema. *Journal of Heart and Lung Transplantation* 1999; 18:1080-1087.
- 45.** Badesch DB, Zamora MR, **Weill D**, and Schwarz MI. Pulmonary capillaritis: a possible histologic form of acute allograft rejection. *Journal of Heart and Lung Transplantation* 1998; 17(4):415-422. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.
- 46.** Terada LS, Hybertson BM, **Weill D**, and Repine JE. XO increases neutrophil adherence to endothelial cells by a dual mechanism. *Journal of Applied Physiology* 1997; 82(3):866-873. My role in this study was to provide technical support in the experimental model for the more senior researchers. My secondary role was to write the sections regarding the scientific methodology.
- 47.** Beaver TM, Fullerton DA, **Weill D**, and Grover FL. Colon perforation after lung transplantation. *Annals of Thoracic Surgery* 1996; 62:839-843. My role in this study was to take the primary role in collecting the clinical data for analysis. My secondary role was to heavily edit the manuscript.

EDITORIALS

- 1.** **Weill D**. Access to Lung Transplantation: The Long and Short of It. *Am J Respir Crit Care Med.* 2016 Mar 15;193(6):605-6.
- 2.** **Weill D**. Twenty years of lung transplantation: areas of improvements and challenges. *Minerva Pneumologica* 2003; 42:139-57.
- 3.** **Weill D**. Donor criteria in lung transplantation: an issue revisited. *Chest* 2002; 121:2029-2031.
- 4.** **Weill D** and Keshavjee S. Lung Transplantation for Emphysema: Two Lungs or One? *Journal of Heart and Lung Transplantation* 2001; 20(7):739-742.
- 5.** **Weill D**. Role of cytomegalovirus in cardiac allograft vasculopathy. *Transplant Infectious Disease* 2001 Suppl 2:3:44-48.

REVIEWS

- 1.** Galbraith D and **Weill D**. Popcorn Lung and Bronchiolitis Obliterans: A Critical Appraisal. *International Archives and Environmental Health* 2008 June 12.
- 2.** Astor TL and **Weill D**. Extracorporeal photopheresis in lung transplantation. *Journal of Cutaneous Medicine and Surgery* 2003 Sep 9.
- 3.** **Weill D**, Mack MJ, and Tennison D. Adverse effects of medications commonly administered to thoracic surgical patients. *Chest Surgery Clinics of North America, Medical Complications of Thoracic Surgery*, August 1999.

BOOK CHAPTERS/ MONOGRAPHS

1. Dhillon GS and **Weill D**. Recipient management before transplantation. Lung Transplantation: Principles and Practice. Editors: Vigneswaran and Garrity, 2016
2. **Weill D**. Asbestos and asbestos-related diseases. Hunter's Diseases of Occupation, 10th Edition, Editors: Baxter, Aw, Cockcroft, Durrington, and Harrington, 2010.
3. **Weill D**. The Clinical Aspects of the Asbestos Associated Diseases. Asbestos and Its Diseases, 1st Edition, Editors: Craighead and Gibbs, 2008.
4. Astor TL and **Weill D**. Oxidative Lung Injury. Textbook of Critical Care, 5th Edition, Editors: Fink, Abraham, Vincent, Kochanek, 2005.
5. **Weill D**. Lung Transplantation. Textbook of Critical Care, 5th Edition, Editors: Fink, Abraham, Vincent, Kochanek, 2005.
6. **Weill D**, Rose C, and King TE. Treatment and prognosis of hypersensitivity pneumonitis. UPTODATE in Pulmonary and Critical Care Medicine, 1997, American Thoracic Society.
7. **Weill D** and Zamora MR. Postoperative care in lung transplantation. Seminars in Respiratory Medicine 1996; 17(2):159-165.
8. **Weill D** and Make B. Oxygen Conserving Devices. Long-Term Oxygen Therapy, New York: Marcel Dekker, 1994; 234-256.

LETTERS

1. **Weill D**, Chatfield E, Cox A Jr, Gamble J, Gibbs G, Wylie A. In reference to Hwang et al. "The Relationship Between Various Exposure Metrics for Elongate Mineral Particles (EMP) in the Taconite Mining and Processing Industry" J Occup Envir Hyg. 2015 Jan 23.
2. Galbraith DA and **Weill D**. Authors' response to Kreiss et al. Int Arch Occup Environ Health 2010 Feb;83(2):237-40.
3. Finley BL, Galbraith DA, and **Weill D**. Comments on respiratory toxicity of diacetyl. Toxicol Sci 2008 Oct;105(2):429-32.
4. Galbraith DA and **Weill D**. Diacetyl and bronchiolitis obliterans. Am J Respir Crit Care Med 2008 Aug 1;178(3):313.
5. **Weill D** and Weill H. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2005 Mar 1; 171(5):527-528.
6. **Weill D** and Zamora MR. Comparison of the efficacy and cost effectiveness of preoperative therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients. Journal of Heart and Lung Transplantation 2000; 19(8):815-6.

ORAL PRESENTATIONS (COMPETITIVE)

1. Dhillon GS, Zamora MR, Roos JE, Sheahan D, Sista RR, Van der Starre P, **Weill D**, Nicolls MR. Lung Transplant Airway Hypoxia: A Diathesis to Fibrosis? American Thoracic Society Annual Meeting, New Orleans, May 2010.
2. **Weill D**, Young R, and McGiffin DC. A Positive Donor Gram Stain Does Not Predict the Development of Pneumonia, Oxygenation, or Duration of Mechanical Ventilation Following Lung Transplantation, International Society of Heart and Lung Transplantation, April 2001.
3. **Weill D**, Young R, And McGiffin DC. The Utility of Open Lung Biopsy Following Lung Transplantation, 4th International Congress on Lung Transplantation, September 2000.
4. **Weill D**, Magee M, Dewey T, and Mack MJ. Impact of Donor Gram Stain on Recipient Outcome Following Lung Transplantation, International Society of Heart and Lung Transplantation, April 2000.
5. **Weill D**, Torres, F, Hodges TN, and Zamora MR. Acute Native Lung Hyperinflation Following Single Lung Transplantation for Emphysema, International Society of Heart and Lung Transplantation, April 1999.
6. **Weill D**. p53 Oncogene Transfers to Non-Small Cell Lung Cancers, American Association of Thoracic Surgeons, May 1998.

Invited Extramural Lectures and Presentations

- April 2016** The Preoperative Selection of Lung Transplant Candidates with Malignancy, ISHLT, Washington D.C.
- February 2016** The Lung Allocation Score: Morbidity, Mortality, and Resource Utilization, The Methodist Hospital, Houston, Texas
- April 2014** The Report on Recipient Selection Consensus Document, ISHLT, San Diego, CA

May 2008 Lung Transplantation: Where We Have Been and Where We Are Going, Stanford University, Medical Grand Rounds

March 2008 Expanding the Donor Pool, Plenary Session, Transplant Growth and Collaborative Meeting, Department of Health and Human Services

December 2006 Cytomegalovirus Infections Following Lung Transplantation, Stanford University, Medical Grand Rounds

February 2006 Lung Transplantation 2006, University of California – Davis, Pulmonary Grand Rounds

December 2004 An Update on Lung Transplantation, University of West Virginia Medical School, Pulmonary Grand Rounds

September 2004 Current Aspects of Lung Transplantation, University of Texas-Southwestern, Pulmonary Grand Rounds

June 2003 Post Transplant Thoracic Malignancies, Texas Transplant Society Annual Meeting

June 2003 An Update on Bronchiolitis Obliterans Syndrome, University of Southern California Medical School, Pulmonary Grand Rounds

March 2003 Expanding the Donor Pool, International Meeting, American Society of Transplant Physicians and Surgeons

February 2003 Lung Transplantation for COPD: Two Lungs, One, or None, Cardiothoracic Transplantation: An International Update, Vail, CO

November 2002 Photopheresis in Lung Transplantation, Johns Hopkins Medical School

October 2002 Lung Transplantation: An Update, University of Colorado Health Sciences Center, Medical Grand Rounds

February 2002 Expanding the Donor Pool, Oregon Health Sciences Center Transplant Grand Rounds

February 2002 Cytomegalovirus Infections in Thoracic Transplantation, University of Texas – San Antonio Transplant Grand Rounds

December 2001 An Update on Immunosuppression, Indiana University/Methodist Hospital Transplant Grand Rounds

February 2001 Lung Transplantation for Bronchioloalveolar Carcinoma, Cardiothoracic Transplantation 2001: An International Update

July 2000 Current Aspects of Lung Transplantation. Medical Grand Rounds, University of Alabama- Birmingham

September 2000 Late Complications Following Lung Transplantation, Lung Transplantation 2000, Mount Sinai Medical Center

June 1997 Tolerance to Acute Lung Injury, Louisiana State University Pulmonary Grand Rounds

BOARD OF DIRECTORS

2014 – Present Isidore Newman School
New Orleans, Louisiana

2016 – Present Next Gen Personal Finance
Palo Alto, California

2014 – Present Rosemary Beach Property Owners Association
Rosemary Beach, Florida